{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:43:13Z","timestamp":1781804593546,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2005,4,13]],"date-time":"2005-04-13T00:00:00Z","timestamp":1113350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s00415-005-0830-z","type":"journal-article","created":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T20:36:36Z","timestamp":1112387796000},"page":"1186-1193","source":"Crossref","is-referenced-by-count":30,"title":["Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events"],"prefix":"10.1007","volume":"252","author":[{"given":"R.","family":"Moretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Antonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cattaruzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,4,13]]},"reference":[{"key":"830_CR1","first-page":"642","volume":"9","author":"Aarsland","year":"1997","unstructured":"Aarsland D, Larsen JP, Cummings JL (1997) Mortality and hallucination in Parkinson\u2019s disease: a four-year longitudinal study. J Neuropsych Clin Neurosci 9:642","journal-title":"J Neuropsych Clin Neurosci"},{"key":"830_CR2","first-page":"5","volume":"65","author":"Alexopoulos","year":"2004","unstructured":"Alexopoulos GS, Streim J, Carpenter D, Docherty JP (2004) Expert Consensus Panel for using antipsychotic drugs in older patients. Using antipsychotic agents in older patients. J Clin Psychiatry 65(S2):5\u201399 (100\u2013102; discussion)","journal-title":"J Clin Psychiatry"},{"key":"830_CR3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4088\/JCP.v62n0810","volume":"62","author":"Ballard","year":"2001","unstructured":"Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, O\u2019Brien J (2001) A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry 62:631\u2013636","journal-title":"J Clin Psychiatry"},{"key":"830_CR4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","volume":"64","author":"Brodaty","year":"2003","unstructured":"Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F, et al. (2003) A randomized placebo-controlled trial of risperidone in the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry 64(2):134\u2013143","journal-title":"J Clin Psychiatry"},{"key":"830_CR5","first-page":"incidence","volume":"homes","author":"Bronskill","year":"2004","unstructured":"Bronskill SE, Anderson GM, Sykora K, Wodchis WP, Gill S, Shulman KI, et al. (2004) Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose and specialist contact. J Am Ger Soc (in press)","journal-title":"Neuroleptic drug therapy in older adults newly admitted to nursing"},{"key":"830_CR6","unstructured":"Committee on Safety on Medicines (2004) Atypical antipsychotic drugs and stroke. http:\/\/medicines.mhra.gov.uk\/2004"},{"key":"830_CR7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1532-5415.1993.tb05945.x","volume":"41","author":"Conwell","year":"1993","unstructured":"Conwell Y, Forbes NT, Cox C, Caine ED (1993) Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc 41:38\u201341","journal-title":"J Am Geriatr Soc"},{"key":"830_CR8","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, et al. (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308\u20132314","journal-title":"Neurology"},{"key":"830_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.1032","volume":"19","author":"De Deyn","year":"2004","unstructured":"De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A (2004) Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry 19(2):115\u2013126","journal-title":"Int J Geriatr Psychiatry"},{"key":"830_CR10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","volume":"53","author":"De Deyn","year":"1999","unstructured":"De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA (1999) A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53: 946\u2013955","journal-title":"Neurology"},{"key":"830_CR11","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1176\/ajp.155.11.1512","volume":"155","author":"Devanand","year":"1998","unstructured":"Devanand DP, Marder K, Michaels KS, et al. (1998) A randomized, placebocontrolled dose-comparison trial of haloperidol for psychoses and disruptive behaviors in Alzheimer\u2019s Disease. Am J Psychiatry 155:1512\u20131520","journal-title":"Am J Psychiatry"},{"key":"830_CR12","unstructured":"Folstein MF, Bylsma FW (1999) Noncognitive symptoms of Alzheimer Disease. In: Terry RD, Katzmann R, Bick L, Sisodia SS (eds) Alzheimer Disease, 2nd Edition, Philadelphia, Lippincott Williams and Wilkins, pp 25\u201337"},{"key":"830_CR13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4088\/JCP.v64n0617","volume":"64","author":"Fontaine","year":"2003","unstructured":"Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF (2003) A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 64(6): 726\u2013730","journal-title":"J Clin Psychiatry"},{"key":"830_CR14","unstructured":"Food and Drug Administration (2003) Safety alert-Risperdal (risperidone). www.fda. gov\/medwatch\/SAFETY\/2003 \/risperdal. htm 2004"},{"key":"830_CR15","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/archneur.1975.00490510088009","volume":"32","author":"Hachinski","year":"1975","unstructured":"Hachinski VC, Iliff LD, Zhilka E, et al. (1975) Cerebral blood flow in dementia. Arch Neurol 32:632\u2013637","journal-title":"Arch Neurol"},{"key":"830_CR16","unstructured":"Health Canada (2004) www.hc-sc.gc.ca\/hpfb-dgpsa\/tpd-dpt\/adverse_e.html 2004"},{"key":"830_CR17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1176\/appi.ajp.161.6.1113","volume":"161","author":"Herrmann","year":"2004","unstructured":"Herrmann N, Mamdani M, Lanct\u00f4t KL (2004) Atypical Antipsychotics and Risk of Cerebrovascular Accidents. Am J Psychiatry 161:1113\u20131115","journal-title":"Am J Psychiatry"},{"key":"830_CR18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004714-200304000-00002","volume":"23","author":"Hwang","year":"2003","unstructured":"Hwang JP, Yang CH, Lee TW, Tsai SJ (2003) The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol 23(2):113\u2013118","journal-title":"J Clin Psychopharmacol"},{"key":"830_CR19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","volume":"60","author":"Katz","year":"1999","unstructured":"Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M (1999) Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 60:107\u2013115","journal-title":"J Clin Psychiatry"},{"key":"830_CR20","first-page":"7","volume":"001","author":"Kaufer","year":"2000","unstructured":"Kaufer D (2000) Treatment of behavioral symptoms in Alzheimer\u2019s disease. Am Acad Neurol San Diego 5TP. 001:7\u201319","journal-title":"Am Acad Neurol San Diego 5TP"},{"key":"830_CR21","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS570>3.0.CO;2-8","volume":"16","author":"Kennedy","year":"2001","unstructured":"Kennedy JS, Zagar A, Bymaster F, Nomios G, Trzepacz PT, Gilmore JA, Rotelli MD, Breier A, Tollefson G (2001) The central cholinergic system profile of olanzapine compared with placebo in Alzheimer\u2019s disease. Int J Geriatr Psych 16:S24\u2013S32","journal-title":"Int J Geriatr Psych"},{"key":"830_CR22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"Lawton","year":"1969","unstructured":"Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179\u2013186","journal-title":"Gerontologist"},{"key":"830_CR23","unstructured":"Lee PE, Gill SS, Freedman M, Bronksill SE, Hillmer MP, Rochon PA (2004) Atypical antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia: systematic review. BMJ, doi:10.1136\/bmj,38125.465579. 55"},{"key":"830_CR24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","volume":"157","author":"Lyketsos","year":"2000","unstructured":"Lyketsos CG, Steinebrg M, Tschanz JT (2000) Mental and behavioural disturbances in dementia: findings from the Cache county Study on Memory in Aging. Am J Psychiatry 157:708\u2013714","journal-title":"Am J Psychiatry"},{"key":"830_CR25","first-page":"61","volume":"14","author":"Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel index. Maryland State Med J 14:61\u201365","journal-title":"Maryland State Med J"},{"key":"830_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1525-8610(04)70343-6","volume":"4","author":"Martin","year":"2003","unstructured":"Martin H, Slyk MP, Deymann S, Cornacchione MJ (2003) Safety profile assessment of risperidone and olanzapine in long term care patients with dementia. J Am Med Dir Assoc 4(4):183\u2013188","journal-title":"J Am Med Dir Assoc"},{"key":"830_CR27","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(72)92775-4","volume":"2","author":"Matthew","year":"1972","unstructured":"Matthew NT, Rivera VM, Meyer JS, Chareny JZ, Hartmann A (1972) Double-blind evaluation of glycerol therapy in acute cerebral infarction. Lancet 2:1327\u20131329","journal-title":"Lancet"},{"key":"830_CR28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4088\/JCP.v60n0504","volume":"60","author":"McManus","year":"1999","unstructured":"McManus DQ, Arvanitis LA, Kowalcyk BB and the Seroquel Trial 48 Study Group (1999) Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 60:292\u2013298","journal-title":"J Clin Psychiatry"},{"key":"830_CR29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/WNL.46.1.130","volume":"46","author":"Mega","year":"1996","unstructured":"Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioural changes in Alzheimer\u2019s disease. Neurology 46:130\u2013135","journal-title":"Neurology"},{"key":"830_CR30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1017\/S104161020000692X","volume":"12","author":"Mintzer","year":"2000","unstructured":"Mintzer JE, Brawman-Mintzer O, Mirski D, Barkin K (2000) Anxiety in the behavioral and psychological symptoms of dementia (BPSD). Int Psychogeriatrics 12(S1):139\u2013142","journal-title":"Int Psychogeriatrics"},{"key":"830_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/153331750301800410","volume":"18","author":"Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A (2003) Treatment of behaviour disorders specific to patients with Alzheimer disease, vascular dementia and parkinsonism: a 24-month follow-up with olanzapine. Am J Alzheimers Dis Other Demen 18(4):205\u2013214","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"830_CR32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/153331750401900215","volume":"19","author":"Moretti","year":"2004","unstructured":"Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A (2004) Anxiety symptoms due to vascular dementia. Olanzapine as a possible treatment: an open study. Am J Alzheimers Dis Other Demen 19(2):81\u201389","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"830_CR33","first-page":"2335","volume":"67","author":"Motsinger","year":"2003","unstructured":"Motsinger CD, Perron GA, Lacy TJ (2003) Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician 67(11):2335\u20132340","journal-title":"Am Fam Physician"},{"key":"830_CR34","unstructured":"Mowat D (2004) CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ 328:1262,doi:10.1136\/bmj0.328.7450.1262-b"},{"key":"830_CR35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/geront\/29.6.798","volume":"29","author":"Novak","year":"1989","unstructured":"Novak M, Guest C (1989) Application of a multidimensional Caregiver Burden Inventory. Gerontologist 29:798\u2013803","journal-title":"Gerontologist"},{"key":"830_CR36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/002383099200500108","volume":"5","author":"Donnell","year":"1992","unstructured":"O\u2019Donnell BF, Drachmen DA, Barnes HJ, Petersen Ke, Swearer JM, Lew RA (1992) Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 5:45\u201352","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"830_CR37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n GC, Tatemichi TK, Erkinjuntti T, et al. (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250\u2013260","journal-title":"Neurology"},{"key":"830_CR38","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1345\/aph.1D050","volume":"37","author":"Schatz","year":"2003","unstructured":"Schatz RA (2003) Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. Ann Pharmacother 37(9):1321\u20131324","journal-title":"Ann Pharmacother"},{"key":"830_CR39","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.1997.03550160083043","volume":"278","author":"Small","year":"1997","unstructured":"Small GW, Rabins PV, Barry PP, Bucholtz NS, DeKosky ST, Ferris SH, et al. (1997) Diagnosis and treatment of Alzheimer disease and related disorder. Consensus statement of the American Geriatric Association for Geriatric Psychiatry, the Alzheimer\u2019s Association and the American Geriatrics society. JAMA 278:1363\u20131371","journal-title":"JAMA"},{"key":"830_CR40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","volume":"57","author":"Street","year":"2000","unstructured":"Street J, Clark S, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A, for the HGEU Study Group (2000) Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer Disease in nursing care facilities. Arch Gen Psychiatry 57:968\u2013976","journal-title":"Arch Gen Psychiatry"},{"key":"830_CR41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0749-0690(05)70073-2","volume":"17","author":"Tariot","year":"2001","unstructured":"Tariot PN, Ryan M, Porsteinsson AP, Loy R, Schneider LS (2001) Pharmacologic therapy for behavioral symptoms of Alzheimer\u2019s Disease. Clinics in Geriatric Medicine 17:359\u2013376","journal-title":"Clinics in Geriatric Medicine"},{"key":"830_CR42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1532-5415.1986.tb05480.x","volume":"34","author":"Tinetti","year":"1986","unstructured":"Tinetti ME (1986) Performance-oriented assessment of mobility problems in elderly patients. J Am Ger Soc 34:119\u2013126","journal-title":"Am Ger Soc"},{"key":"830_CR43","unstructured":"Wooltorton E (2004) Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 170(9):doi:10.1503\/cmaj0.1040539"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-0830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-005-0830-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-0830-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:04:01Z","timestamp":1559070241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-005-0830-z"}},"subtitle":["A controlled, open-label study"],"short-title":[],"issued":{"date-parts":[[2005,4,13]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s00415-005-0830-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,13]]}}}